Population pharmacokinetics: Drugmakers seek clarity and additions to revised FDA guidance
About a dozen drugmakers and industry groups recently offered their opinions on a revised FDA draft guidance related to population pharmacokinetics (PK) analyses submitted as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
